Strategies to boost immunity by vaccination with known leukemia-antigens in combination with IFN or strategies for IFN maintenance therapy after imatinib treatment, as suggested by the results of a prospective clinical trial in patients treated with imatinib and IFN [29], might improve responses in patients. Here, IFNA1 is linked to leukemia.